Brokerages Set Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Price Target at $55.80

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $55.80.

PTHS has been the subject of a number of recent research reports. Roth Mkm lowered their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Piper Sandler initiated coverage on Pelthos Therapeutics in a report on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Finally, Oppenheimer upped their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th.

Insider Buying and Selling at Pelthos Therapeutics

In related news, Director Todd C. Davis acquired 35,948 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $27.82 per share, for a total transaction of $1,000,073.36. Following the completion of the transaction, the director directly owned 75,834 shares of the company’s stock, valued at $2,109,701.88. The trade was a 90.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 2,228 shares of company stock valued at $48,412 over the last ninety days. Corporate insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On Pelthos Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC raised its position in shares of Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after acquiring an additional 193,307 shares during the last quarter. Boothbay Fund Management LLC raised its position in shares of Pelthos Therapeutics by 279.8% during the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the last quarter. J. Goldman & Co LP bought a new position in shares of Pelthos Therapeutics during the fourth quarter worth about $2,418,000. Cantor Fitzgerald L. P. bought a new position in shares of Pelthos Therapeutics during the fourth quarter worth about $1,085,000. Finally, Diadema Partners LP raised its position in shares of Pelthos Therapeutics by 138.1% during the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares during the last quarter. 77.96% of the stock is currently owned by institutional investors.

Pelthos Therapeutics Price Performance

Shares of PTHS stock opened at $29.00 on Monday. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. Pelthos Therapeutics has a twelve month low of $11.20 and a twelve month high of $54.29. The company has a market cap of $100.92 million, a P/E ratio of -1.41 and a beta of 3.16. The stock’s fifty day simple moving average is $25.67.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The business had revenue of $10.91 million during the quarter. As a group, equities research analysts anticipate that Pelthos Therapeutics will post -12.63 earnings per share for the current fiscal year.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).